On September 2, 2026, Precision Dose Inc. won FDA approval for ANDA214523, laying the groundwork for market expansion and revenue generation for the company's portfolio. The approval significantly strengthens Precision Dose Inc.'s standing in the generic market, positioning it for competitive gain and improved financial performance.